At a glance
ClinicalIndex Comparison RecordPhase 2Active· 325 enrolled
Drug / intervention
XEN1101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, With an Open-label Extension
In Brief
A Phase 2 clinical trial evaluating XEN1101 for Focal Epilepsy. Active but no longer recruiting, targeting 325 participants across 95 sites in 9 countries.
Detailed Summary
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFocal Epilepsy
CountriesCanada, Georgia, Germany, Italy, Moldova, Spain, Ukraine, United Kingdom, United States
CollaboratorsNovotech Health Holdings Pte. Ltd.
Timeline
Phase 2Active
20192020202120222023202420252026202720282029
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionSep 2021
TodayJul 2026
Study CompletionOct 2028
First PostedJan 8, 2019
Enrollment StartJan 30, 2019
Primary CompletionSep 2, 2021
Study CompletionOct 1, 2028
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.5 years ago
Interventions
XEN1101drug
Oral dose